Profile data is unavailable for this security.
About the company
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
- Revenue in USD (TTM)0.00
- Net income in USD-8.96m
- Incorporated2019
- Employees9.00
- LocationRevelation Biosciences Inc4660 Lajolla Village Drive, Suite 100SAN DIEGO 92122United StatesUSA
- Phone+1 (650) 800-3717
- Fax+1 (302) 645-1280
- Websitehttps://www.revbiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novelstem International Corp | 12.00k | -4.19m | 2.81m | 15.00 | -- | -- | -- | 234.41 | -0.0893 | -0.0893 | 0.0003 | -0.0416 | 0.0053 | -- | 2.00 | -- | -171.11 | -- | -188.15 | -- | -- | -- | -32,373.50 | -- | -- | -9.82 | 2.20 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.01m | 2.82m | 3.00 | -- | -- | -- | -- | -0.1397 | -0.1397 | 0.00 | -0.8107 | 0.00 | -- | -- | 0.00 | -457.45 | -- | -- | -- | -- | -- | -- | -- | -- | -35.84 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Regen BioPharma Inc | 236.58k | -851.69k | 2.86m | 1.00 | -- | -- | -- | 12.09 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Axim Biotechnologies Inc | 39.77k | -8.06m | 2.91m | 6.00 | -- | -- | -- | 73.29 | -0.0366 | -0.0366 | 0.0001 | -0.0311 | 0.0095 | -- | -- | 6,628.33 | -193.43 | -154.34 | -- | -390.73 | -- | -- | -20,265.75 | -36,362.71 | -- | -0.62 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Veritas Farms Inc | 730.65k | -6.15m | 2.95m | 17.00 | -- | 14.57 | -- | 4.04 | -0.1319 | -0.1319 | 0.0136 | 0.0013 | 0.0877 | 0.8064 | 7.80 | 42,979.41 | -69.02 | -72.11 | -123.21 | -93.59 | -220.09 | 24.07 | -787.27 | -177.79 | 0.1392 | -5.56 | 0.95 | -- | -63.42 | -0.9427 | 23.68 | -- | -52.93 | -- |
| Navidea Biopharmaceuticals Inc | 610.00 | -8.81m | 3.00m | 11.00 | -- | -- | -- | 4,922.18 | -0.2086 | -0.0547 | 0.00001 | -0.0327 | 0.0001 | 0.1529 | 0.0066 | 55.45 | -143.97 | -169.68 | -- | -753.52 | -8,103.28 | 91.34 | -1,411,062.00 | -1,938.53 | 0.5066 | -- | -- | -- | -87.65 | -48.49 | -46.75 | -- | 63.23 | -- |
| Biostax Corp | 0.00 | -1.65m | 3.01m | -- | -- | -- | -- | -- | -0.0198 | -0.0198 | 0.00 | -0.0456 | 0.00 | -- | -- | -- | -193.36 | -75.14 | -- | -- | -- | -- | -- | -- | -- | -8.97 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -8.96m | 3.04m | 9.00 | -- | 0.3206 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Finch Therapeutics Group Inc | 107.00k | -74.75m | 3.08m | 18.00 | -- | 0.1347 | -- | 28.81 | -46.59 | -46.59 | 0.0667 | 14.25 | 0.001 | -- | 1.49 | -- | -68.48 | -- | -74.93 | -- | -- | -- | -69,863.55 | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -10.06m | 3.11m | 21.00 | -- | 0.518 | -- | -- | -1.93 | -1.93 | 0.00 | 0.5447 | 0.00 | -- | -- | 0.00 | -125.53 | -132.00 | -149.91 | -157.28 | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| AccuStem Sciences Inc | 0.00 | -2.05m | 3.14m | 3.00 | -- | -- | -- | -- | -0.1807 | -0.1807 | 0.00 | -0.1861 | 0.00 | -- | -- | 0.00 | -382.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.26 | -- | -- | -- |
| Onconetix Inc | 58.47k | -37.41m | 3.15m | 12.00 | -- | -- | -- | 53.84 | -2.09 | -2.09 | 0.0034 | 2.63 | 0.001 | -- | 0.6301 | 4,872.50 | -65.73 | -- | -87.29 | -- | -1,927.76 | -- | -63,981.00 | -- | 0.3185 | -19.88 | 0.1292 | -- | -- | -- | -176.78 | -- | -- | -- |
| Optimus Healthcare Services Inc | 1.27m | -7.79m | 3.20m | 17.00 | -- | -- | -- | 2.53 | -0.1948 | -0.1948 | 0.0317 | -0.1291 | 0.2595 | -- | 2.16 | 74,453.53 | -159.79 | -- | -2,228.37 | -- | 77.90 | -- | -615.77 | -- | 0.1525 | -15.41 | 21.18 | -- | -- | -- | -- | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.25m | 40.00 | -- | 0.0879 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Data as of May 16 2024. Currency figures normalised to Revelation Biosciences Inc's reporting currency: US Dollar USD
1.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Walleye Capital LLCas of 31 Dec 2023 | 13.78k | 0.84% |
| Sabby Management LLCas of 31 Dec 2023 | 13.44k | 0.82% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2023 | 1.87k | 0.11% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.19k | 0.07% |
| Citadel Securities LLCas of 31 Dec 2023 | 805.00 | 0.05% |
| Securities America Advisors, Inc.as of 31 Mar 2024 | 300.00 | 0.02% |
| Tower Research Capital LLCas of 31 Dec 2023 | 76.00 | 0.01% |
| UBS Securities LLCas of 31 Dec 2023 | 5.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 4.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 3.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
